Eli Lilly and Co is to expand its pharmaceutical pipeline with the acquisition of Sigilon Therapeutics Inc of Cambridge, US, which has a pre-clinical asset for type 1 diabetes. The two companies have been developing the asset, an encapsulated cell therapy called SIG-002, since 2018. The product is in lead optimisation and poised to enter clinical development.
